U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C20H38N4O4
Molecular Weight 398.5401
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIMORPHOLAMINE

SMILES

CCCCN(CCN(CCCC)C(=O)N1CCOCC1)C(=O)N2CCOCC2

InChI

InChIKey=HZTMGWSBSDLALI-UHFFFAOYSA-N
InChI=1S/C20H38N4O4/c1-3-5-7-21(19(25)23-11-15-27-16-12-23)9-10-22(8-6-4-2)20(26)24-13-17-28-18-14-24/h3-18H2,1-2H3

HIDE SMILES / InChI

Description

Dimorpholamine is reported as an ingredient of Theraptique in Japan. Dimorpholamine stimulates the respiratory and circulatory centers to increase the respiratory volume and blood pressure. It is indicated for the respiratory and circulatory insufficiency due to shock, hypnotic intoxication. drowning, pneumonia, and high fever.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Theraptique

PubMed

Sample Use Guides

In Vivo Use Guide
30-60 mg (1-2 ampoules) via the intramuscular route. If necessary, the same dose may be given repeatedly unless the daily dose exceeds 200 mg (6.5 ampoules).
Route of Administration: Intramuscular
In Vitro Use Guide
Low concentrations (about 2 x 10(-5) g/ml) of dimorpholamine potentiate the twitch contraction of frog sartorius muscle. In relatively high concentrations of 10(-4)--10(-3) g/ml, however, the potentiation was followed by depression.